Aim­ing to re­bound from blun­ders years ago, Celldex touts a Phase Ib win with sights set on Xo­lair

Fol­low­ing mul­ti­ple high-pro­file mis­steps sev­er­al years ago, the folks over at Celldex Ther­a­peu­tics be­gan chart­ing a path to re­demp­tion that would take on Roche and No­var­tis’ block­buster Xo­lair fran­chise. That path got a boost Fri­day with a da­ta read­out the com­pa­ny says po­si­tions it well against the phar­ma gi­ants.

Celldex re­port­ed re­sults from a Phase Ib study for their mon­o­clon­al an­ti­body CDX-0159 to treat two con­di­tions that cause se­vere and de­bil­i­tat­ing hives. The Hamp­ton, NJ-based biotech said that among 19 pa­tients who re­ceived a full dose of the an­ti­body, 18 achieved a com­plete re­sponse and the 19th saw a par­tial re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER